Dr Kelly's team synthesized a PDC series of PDCs designed to treat pulmonary fibrosis precisely, combining the kinase inhibitor nintedanib with a mimetic peptide chain targeting the αVβ6 integrin. Their antifibrotic activity is currently being evaluated in a mouse model of pulmonary fibrosis.